Molecular Cancer Therapeutics · 2004 · 24 citations · 41 references
Life SciencesOncologyPharmacologyApoptosisCell SignalingSignal TransductionApoptosis RegulationApoptotic Signal TransductionApoptotic SignalingCaspase ActivationCell DeathDeath ReceptorsApoptosis Regulation By KinasesApoptosis TargetingApoptosis-inducing FactorDeath Ligand ResistanceDeath Ligand SignalingDeath-associated Protein Kinase SignalingTumor Necrosis Factor-related Apoptosis-inducing Ligand ReceptorsWestern Blot Analysis
Abstract Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a highly promising candidate for the treatment of cancer because it elicits cell death in the majority of tumor cells while sparing most normal cells. Some cancers, however, display resistance to TRAIL, suggesting that treatment with TRAIL alone may be insufficient for cancer therapy. In the present study, we explored whether the apoptotic responsiveness of PC-3 prostate cancer cells to TRAIL could be enhanced by targeting the novel protein kinase C (PKC) isoform η. Transfection of PC-3 cells with second-generation chimeric antisense oligonucleotides against PKCη caused a time- and dose-dependent knockdown of PKCη, as revealed by real-time RT-PCR and Western blot analyses. Knockdown of PKCη resulted in a marked amplification of TRAIL's cytotoxic activity. Cell killing could be substantially prevented by the pan-caspase inhibitor z-VAD-fmk. In addition, PKCη knockdown and administration of TRAIL significantly synergized in activation of caspase-3 and internucleosomal DNA fragmentation. Knockdown of PKCη augmented TRAIL-induced dissipation of the mitochondrial transmembrane potential and release of cytochrome c from mitochondria into the cytosol, indicating that PKCη acts upstream of mitochondria. We conclude that PKCη represents a considerable resistance factor with respect to TRAIL and a promising target to exploit the therapeutic potential of TRAIL.
41
Two CD95 (APO‐1/Fas) signaling pathways
Carsten Scaffidi · The EMBO Journal · 1998 · 3K citations · Full text
Inhibition of death receptor signals by cellular FLIP
Martin Irmler, Margot Thome, Michael Hahne et al. · Nature · 1997 · 2.6K citations · Full text